Day: May 7, 2025

Southlake, TX, May 07, 2025 (GLOBE NEWSWIRE) — HeartSciences Inc. (Nasdaq:HSCS) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced the appointment of Dr. Girish Nadkarni, MD, Dr. Joshua Lampert, MD, and Dr. Akhil Vaid, MBBS, to its Scientific Advisory Board. These appointments underscore HeartSciences’ commitment to advancing and transforming data-driven AI-ECG technology. “We are honored to welcome Dr. Girish Nadkarni, Dr. Joshua Lampert, and Dr. Akhil Vaid to our Scientific Advisory Board,” said Andrew Simpson, CEO of HeartSciences. “Each of these distinguished leaders brings a wealth of expertise at the intersection of cardiology,...

Geneva, Switzerland, May 07, 2025 (GLOBE NEWSWIRE) — QVault TPM Now Compliant with ML-DSA-87 and ML-KEM-1024, Leverages the Most Secure NIST-Standardized CRYSTALS-Dilithium and Kyber Algorithms for Quantum-Resistant Protection SEALSQ Corp (NASDAQ: LAES) (“SEALSQ” or “Company”), a company that focuses on developing and selling Semiconductors, PKI, and Post-Quantum technology hardware and software products, today announced that its QVault Trusted Platform Module (TPM) is fully compliant with ML-DSA-87 and ML-KEM-1024, the highest-security parameter sets of the NIST-standardized CRYSTALS-Dilithium (ML-DSA) and CRYSTALS-Kyber (ML-KEM) algorithms. This milestone reinforces SEALSQ’s position as a trusted provider of quantum-resistant security solutions, addressing the stringent requirements of defense, IoT, automotive,...

ROCKVILLE, Md., May 07, 2025 (GLOBE NEWSWIRE) — Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced the pricing of its “reasonable best efforts” public offering for the purchase and sale of up to 6,818,180 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 6,818,180 shares of common stock at a combined offering price of $1.10 per share and accompanying warrant (the “Offering”). The Company expects to receive aggregate gross proceeds of approximately $7.5 million, before deducting placement agent fees and other offering expenses, and assuming no exercise of the warrants. The warrants will have an exercise price of $1.10...

Flagship Deployment of NEXT Platform Reinforces Vicon’s Growth Momentum in Fiscal 2025 Hauppauge, NY, May 07, 2025 (GLOBE NEWSWIRE) — – Vicon Industries, a subsidiary of Cemtrex Inc. (Nasdaq: CETX) and a leading provider of advanced security and surveillance solutions, today announced it has secured a significant new order valued at approximately $1 million from one of Saudi Arabia’s leading media and broadcasting organizations. The order includes the company’s latest innovation, the NEXT Modular Sensor System, and marks a major milestone for Vicon’s expansion into the Gulf region. The comprehensive deployment spans hundreds of advanced starlight dome and bullet cameras, enterprise-grade Valerus video management licenses, and multiple high-capacity recording servers, all supported by Vicon’s award-winning software and hardware...

Enrollment completed for the 6-week interim analysis with 24 of the 36 planned patients now enrolled  Company on track to report interim biomarker data from the first 12 patients imminently Completion of patient enrollment and topline results expected Q3 2025 LA JOLLA, CA, May 07, 2025 (GLOBE NEWSWIRE) — GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that enrollment for the 6 week interim analysis is complete with 24 of the 36 planned patients randomized in its ongoing Phase 2a study evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (“IPF”). “We are pleased with the progress made in this Phase 2a biomarker study....

April same-store sales increased 4.3% year-over-year* NEWARK, N.J., May 07, 2025 (GLOBE NEWSWIRE) — NRSInsights, a provider of sales data and analytics drawn from retail transactions processed through the National Retail Solutions (NRS) point-of-sale (POS) platform, today announced comparative retail same-store sales results for April 2025. As of April 30, 2025, the NRS retail network comprised approximately 35,600 active terminals nationwide, scanning purchases at approximately 31,000 independent retailers including convenience stores, bodegas, liquor stores, grocers, and tobacco and sundries sellers, predominantly serving urban consumers. April Highlights* (*Same-store sales, unit sales, transactions, and average price data refer to April 2025 and are compared to April 2024 unless otherwise noted. All comparisons are provided...

MELVILLE, N.Y., May 07, 2025 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, is pleased to announce that its Vice President of Research and Development, Francisco Silva, will present an update on its ongoing Phase 2 clinical trial of BRTX-100 in chronic lumbar disc disease (cLDD) at the International Society for Cell & Gene Therapy (“ISCT”) 2025 Annual Meeting, taking place May 7 – 10, 2025 in New Orleans, LA. “We are very pleased to have been selected to share a BRTX-100 clinical update with clinicians, researchers, and regulators at ISCT 2025, one of the most prestigious and clinically focused regenerative medicine meetings globally,” said Lance Alstodt, BioRestorative’s...

Strategic Collaboration Marks PetMeds’ Latest Move in Expanding Its Pet Healthcare Ecosystem DELRAY BEACH, Fla. and OAKLAND, Calif., May 07, 2025 (GLOBE NEWSWIRE) — PetMed Express, Inc., parent company of PetMeds and PetCareRx (Nasdaq: PETS), today announced a new strategic partnership with virtual veterinary care provider Dutch. The collaboration marks PetMeds’ latest move to expand its provider ecosystem with affordable, accessible pet healthcare options. The new partnership will enable pet parents to leverage Dutch’s convenient technology and veterinary team to secure prescriptions for PetMeds’ broad selection of medications in a timely manner. “This partnership expands the accessibility of pet telemedicine, which can help fill gaps in care, as the nationwide vet shortage has left more than 129 million Americans without easy...

WHITTIER, Calif., May 07, 2025 (GLOBE NEWSWIRE) — First Pacific Bancorp (the “Company”) (OTC Pink: FPBC), the holding company for First Pacific Bank (the “Bank”), today reported consolidated results for the first quarter ending March 31, 2025, marking its eighth consecutive quarter of profitability. The Company remains well-capitalized, with a healthy liquidity position supported by a stable core deposit base and access to substantial sources of liquidity. Highlights for the first quarter of 2025 include:Total assets ended the first quarter 2025 at $456 million, up $23 million from $433 million at year end 2024. Total deposits ended the first quarter 2025 at $390 million, up $39 million since year end 2024. Total loans ended the first quarter 2025 at $294 million, up $17 million from year end 2024. Asset quality remains excellent...

BERKELEY HEIGHTS, NJ, May 07, 2025 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines, today announced that it expects to implement a 1-for-16 reverse stock split on its shares of common stock effective May 12, 2025, with trading to begin on a split-adjusted basis at the market open on that day. Trading in the shares of common stock will continue on The Nasdaq Capital Market under the symbol “CYCC”. The new CUSIP number for the shares of common stock following the reverse stock split is 23254L884. Upon the effectiveness of the reverse stock split, every 16 shares of the Company’s issued and outstanding shares of common stock will automatically convert into one issued and outstanding share of common stock. No fractional...